Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial
Diabetes Care · 01.09.2025 · 48 (9) · 1622-1627
DOI: 10.2337/dc25-0763 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Diabetes Care, online erschienen am 22.07.2025. Verfasst von Andrea Mari und 9 weiteren Autor:innen. Beteiligte Einrichtung: CNR Institute of Neuroscience, Padova, Italy. Hauptthemen laut MEDLINE: Insulin Resistance, Insulin-Secreting Cells, Obesity, Overweight. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
OBJECTIVE We assessed insulin sensitivity and β-cell function in adults with obesity/overweight, without diabetes, treated with tirzepatide for 72 weeks. RESEARCH DESIGN AND METHODS This post hoc analysis from the Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) trial investigated tirzepatide versus placebo in 2,539 participants with BMI ≥27 kg/m2 and either prediabetes or normoglycemia at baseline. Model-derived parameters of β-cell function and insulin sensitivity were assessed from oral glucose tolerance tests. RESULTS At week 72, tirzepatide treatment was associated with body weight reduction and improvements in insulin sensitivity and β-cell function measures overall and in participants with prediabetes or normoglycemia. In multivariate regression models, improvements in insulin sensitivity were associated mostly with weight reduction and partly with tirzepatide treatment, whereas enhancement in β-cell function was mostly associated with tirzepatide treatment. CONCLUSIONS In adults with obesity/overweight without type 2 diabetes, tirzepatide treatment was associated with improved β-cell function and insulin sensitivity, partly independent of weight reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CNR Institute of Neuroscience, Padova, Italy.
- Eli Lilly and Company, Indianapolis, IN.
- Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, the Netherlands.
- CNR Institute of Clinical Physiology, Pisa, Italy.
ORCID-Profile: Andrea Mari
Förderung
- Eli Lilly and Company
Zitieren
APA
Mari, A., Stefanski, A., van Raalte, D. H., Ma, X., LaBell, E. S., Fan, L., Lee, C. J., Thomas, M. K., Bunck, M. C., & Ferrannini, E. (2025). Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial. Diabetes Care, 48(9), 1622-1627. https://doi.org/10.2337/dc25-0763
Vancouver
Mari A, Stefanski A, van Raalte DH, Ma X, LaBell ES, Fan L, et al. Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial. Diabetes Care. 2025;48(9):1622-1627. doi:10.2337/dc25-0763
BibTeX
@article{Mari2025,
author = {Mari, Andrea and Stefanski, Adam and van Raalte, Daniel H and Ma, Xiaosu and LaBell, Elizabeth S and Fan, Ludi and Lee, Clare J and Thomas, Melissa K and Bunck, Mathijs C and Ferrannini, Ele},
title = {Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial},
journal = {Diabetes Care},
year = {2025},
volume = {48},
number = {9},
pages = {1622--1627},
doi = {10.2337/dc25-0763}
}
EUVIMED